Table 4.
Topical steroid preparations implicated in reported adverse effects
| Number of patients (n=485), n (%)* | |
|---|---|
| Clobetasol propionate 0.05% | 334 (68.87) |
| Alone | 7 (1.44) |
| Combinations | 327 (67.42) |
| Clobetasol propionate with- | |
| Ofloxacin + ornidazole + terbinafine** | 144 (29.69) |
| Gentamicin/neomycin + antifungal (miconazole/clotrimazole) | 64 (13.20) |
| Ketoconazole + tolnaftate gentamicin + clioquinol** | 63 (12.99) |
| Gentamicin/neomycin | 38 (7.84) |
| Salicylic acid | 11 (2.27) |
| Other combinations | 7 (1.44) |
| Betamethasone | 138 (28.45) |
| Alone | 20 (4.12) |
| Combinations | 118 (24.33) |
| Betamethasone with- | |
| Gentamicin/neomycin + antifungal (miconazole/clotrimazole) | 46 (9.48) |
| Gentamicin + tolnaftate + clioquinol** | 36 (7.42) |
| Gentamicin/neomycin | 12 (2.47) |
| Clioquinol | 16 (3.30) |
| Other combinations | 8 (1.65) |
| Mometasone in combinations | 33 (6.80) |
| Other steroids | 12 (2.47) |
| Total | 517# |
*28 patients were using more than one steroid preparation, **Banned by Government of India with effect from September 13, 2018